Sotaro Sadahiro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6128253/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Comparison between oral antibiotics and probiotics as bowel preparation for elective colon cancer surgery to prevent infection: Prospective randomized trial. Surgery, 2014, 155, 493-503.	1.0	122
2	Impact of postoperative complications on the colorectal cancer survival and recurrence: analyses of pooled individual patients' data from three large phase III randomized trials. Cancer Medicine, 2017, 6, 1573-1580.	1.3	73
3	Recurrence patterns after curative resection of colorectal cancer in patients followed for a minimum of ten years. Hepato-Gastroenterology, 2003, 50, 1362-6.	0.5	72
4	Detection of tumor cells in the portal and peripheral blood of patients with colorectal carcinoma using competitive reverse transcriptase-polymerase chain reaction. Cancer, 2001, 92, 1251-1258.	2.0	49
5	Prophylactic hepatic arterial infusion chemotherapy for the prevention of liver metastasis in patients with colon carcinoma. Cancer, 2004, 100, 590-597.	2.0	45
6	Monitoring of Serum Carcinoembryonic Antigen Levels after Curative Resection of Colon Cancer: Cutoff Values Determined according to Preoperative Levels Enhance the Diagnostic Accuracy for Recurrence. Oncology, 2017, 92, 276-282.	0.9	41
7	Detection of Carcinoembryonic Antigen Messenger RNA-Expressing Cells in Peripheral Blood 7ÂDays After Curative Surgery is a Novel Prognostic Factor in Colorectal Cancer. Annals of Surgical Oncology, 2007, 14, 1092-1098.	0.7	40
8	An assessment of the mucous component in carcinoma of the colon and rectum. Cancer, 1989, 64, 1113-1116.	2.0	37
9	Risk Factors for Peritoneal Recurrence in Stage II to III Colon Cancer. Diseases of the Colon and Rectum, 2018, 61, 803-808.	0.7	36
10	Phase I/II Study of Preoperative Concurrent Chemoradiotherapy with S-1 for Locally Advanced, Resectable Rectal Adenocarcinoma. Oncology, 2011, 81, 306-311.	0.9	33
11	Feasibility of a novel weekday-on/weekend-off oral UFT schedule as postoperative adjuvant chemotherapy for colorectal cancer. Cancer Chemotherapy and Pharmacology, 2000, 46, 180-184.	1.1	26
12	Predictive Factors of Tumor Shrinkage and Histological Regression in Patients who Received Preoperative Radiotherapy for Rectal Cancer. Japanese Journal of Clinical Oncology, 2004, 34, 740-746.	0.6	25
13	Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. Journal of the National Cancer Institute, 2021, 113, 1693-1704.	3.0	25
14	Biopsy Specimens Obtained 7 Days After Starting Chemoradiotherapy (CRT) Provide Reliable Predictors of Response to CRT for Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1232-1238.	0.4	24
15	Risk scores as useful predictors of perioperative complications in patients with rectal cancer who received radical surgery. International Journal of Clinical Oncology, 2017, 22, 324-331.	1.0	24
16	Phase II Study of Preoperative Concurrent Chemoradiotherapy with S-1 plus Bevacizumab for Locally Advanced Resectable Rectal Adenocarcinoma. Oncology, 2015, 88, 49-56.	0.9	23
17	Relation between Carcinoembryonic Antigen Levels in Colon Cancer Tissue and Serum Carcinoembryonic Antigen Levels at Initial Surgery and Recurrence. Oncology, 2016, 91, 85-89.	0.9	23
18	Optimal duration of prophylactic antibiotic administration for elective colon cancer surgery: A randomized, clinical trial. Surgery, 2011, 149, 171-178.	1.0	22

#	Article	IF	CITATIONS
19	Clinical impact of tumor location on the colon cancer survival and recurrence: analyses of pooled data from three large phase <scp>III</scp> randomized clinical trials. Cancer Medicine, 2017, 6, 2523-2530.	1.3	21
20	Detection of Carcinoembryonic Antigen Messenger RNA–Expressing Cells in Portal and Peripheral Blood During Surgery Does Not Influence Relapse in Colorectal Cancer. Annals of Surgical Oncology, 2005, 12, 988-994.	0.7	19
21	Mucinous components assessed by magnetic resonance imaging in primary rectal cancer tissue before and after chemoradiotherapy and tumor response. International Journal of Colorectal Disease, 2018, 33, 1135-1138.	1.0	19
22	Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study. British Journal of Cancer, 2019, 120, 689-696.	2.9	19
23	Molecular determinants of folate levels after leucovorin administration in colorectal cancer. Cancer Chemotherapy and Pharmacology, 2010, 65, 735-742.	1.1	17
24	Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer. Cancer Chemotherapy and Pharmacology, 2012, 70, 285-291.	1.1	17
25	Preventive effects of a synthetic absorbable antiadhesive film (seprafilm) on small bowel obstruction in patients who underwent elective surgery for colon cancer: A randomized controlled trial. Journal of Surgical Oncology, 2019, 120, 1038-1043.	0.8	17
26	Effects of preoperative immunochemoradiotherapy and chemoradiotherapy on immune responses in patients with rectal adenocarcinoma. Anticancer Research, 2010, 30, 993-9.	0.5	17
27	Prognostic Factors in Patients with Synchronous Peritoneal Carcinomatosis (PC) Caused by a Primary Cancer of the Colon. Journal of Gastrointestinal Surgery, 2009, 13, 1593-1598.	0.9	16
28	The size of retrieved lymph nodes correlates with the number of retrieved lymph nodes and is an independent prognostic factor in patients with stage II colon cancer. International Journal of Colorectal Disease, 2015, 30, 1685-1693.	1.0	16
29	A pharmacological study of the weekday-on/weekend-off oral UFT schedule in colorectal cancer patients. Cancer Chemotherapy and Pharmacology, 2001, 47, 457-460.	1.1	15
30	Relationship between histologic response and the degree of tumor shrinkage after chemoradiotherapy in patients with locally advanced rectal cancer. Journal of Surgical Oncology, 2014, 109, 659-664.	0.8	15
31	Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials. Journal of Cancer, 2017, 8, 4057-4064.	1.2	15
32	The Number of Natural Killer Cells in the Largest Diameter Lymph Nodes Is Associated with the Number of Retrieved Lymph Nodes and Lymph Node Size, and Is an Independent Prognostic Factor in Patients with Stage II Colon Cancer. Oncology, 2018, 95, 288-296.	0.9	15
33	Usefulness of Preoperative Mechanical Bowel Preparation in Patients with Colon Cancer who Undergo Elective Surgery: A Prospective Randomized Trial Using Oral Antibiotics. Digestive Surgery, 2020, 37, 192-198.	0.6	15
34	Does 1 Year Adjuvant Chemotherapy with Oral 5-FUs in Colon Cancer Reduce the Peak of Recurrence in 1 Year and Provide Long-term OS Benefit?. Japanese Journal of Clinical Oncology, 2011, 41, 299-302.	0.6	14
35	Hematogenous Metastatic Patterns of Curatively Resected Colon Cancer Were Different from Those of Stage IV and Autopsy Cases. Japanese Journal of Clinical Oncology, 2013, 43, 444-447.	0.6	13
36	Relations of Changes in Serum Carcinoembryonic Antigen Levels before and after Neoadjuvant Chemoradiotherapy and after Surgery to Histologic Response and Outcomes in Patients with Locally Advanced Rectal Cancer. Oncology, 2018, 94, 167-175.	0.9	12

SOTARO SADAHIRO

#	Article	IF	CITATIONS
37	Clinical Signatures of Mucinous and Poorly Differentiated Subtypes of Colorectal Adenocarcinomas by a Propensity Score Analysis of an Independent Patient Database from Three Phase III Trials. Diseases of the Colon and Rectum, 2018, 61, 461-471.	0.7	12
38	Estimation of the Time of Pulmonary Metastasis in Colorectal Cancer Patients with Isolated Synchronous Liver Metastasis. Japanese Journal of Clinical Oncology, 2005, 35, 18-22.	0.6	11
39	Optimal sutures for use in the abdomen: an evaluation based on the formation of adhesions and abscesses. Surgery Today, 2013, 43, 412-417.	0.7	11
40	Clinical significance of and future perspectives for hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer. Surgery Today, 2013, 43, 1088-1094.	0.7	11
41	Treatment Rationale and Study Design for Clinical Trial on the Efficacy of UFT/LV for Stage II Colorectal Cancer With Risk Factors for Recurrence (JFMC46-1201). Clinical Colorectal Cancer, 2015, 14, 277-280.	1.0	11
42	Phase I/II Study of 24-Hour Infusion of Irinotecan Combined with Oral UFT for Metastatic Colorectal Cancer. Chemotherapy, 2008, 54, 140-146.	0.8	10
43	A comparison of the localization of rectal carcinomas according to the general rules of the Japanese classification of colorectal carcinoma (JCCRC) and Western guidelines. Surgery Today, 2017, 47, 1086-1093.	0.7	10
44	Effects of chemoradiotherapy on lymph nodes in patients with rectal adenocarcinoma: evaluation of numbers and sizes of retrieved lymph nodes inside and outside the radiation field. Anticancer Research, 2014, 34, 4195-200.	0.5	10
45	Preliminary study on the optimal dosage schedule for oral tegafur/uracil (UFT) chemotherapy. International Journal of Clinical Oncology, 1998, 3, 7-12.	1.0	9
46	Intraoperative radiation therapy for curatively resected rectal cancer. Diseases of the Colon and Rectum, 2001, 44, 1689-1695.	0.7	9
47	Safety analysis of two different regimens of uracil–tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18Âmonths of treatment: JFMC33-0502 trial. Cancer Chemotherapy and Pharmacology, 2014, 73, 1253-1261.	1.1	9
48	Significance of the mucinous component in the histopathological classification of colon cancer. Surgery Today, 2016, 46, 303-308.	0.7	9
49	Pharmacokinetics of 5-Fluorouracil Following Hepatic Intra-arterial Infusion in a VX2 Hepatic Metastasis Model. Japanese Journal of Clinical Oncology, 2003, 33, 377-381.	0.6	8
50	Tattooing improves the detection of small lymph nodes and increases the number of retrieved lymph nodes in patients with rectal cancer who receive preoperative chemoradiotherapy: A randomized controlled clinical trial. American Journal of Surgery, 2018, 215, 563-569.	0.9	8
51	Outcomes of Local Excision plus Chemoradiotherapy in Patients with T1 Rectal Cancer. Oncology, 2018, 95, 246-250.	0.9	8
52	Distribution of Neuroendocrine Marker-Positive Cells in Colorectal Cancer Tissue and Normal Mucosal Tissue: Consideration of Histogenesis of Neuroendocrine Cancer. Oncology, 2019, 97, 294-300.	0.9	8
53	Tumor-Infiltrating Lymphocytes in Biopsy Specimens Obtained 7 Days after Starting Chemoradiotherapy for Rectal Cancer Are Predictors of the Response to Chemoradiotherapy. Oncology, 2020, 98, 869-875.	0.9	8
54	Thymidine phosphorylase expression and effect of doxifluridine: A phase II study. Oncology Reports, 2001, 8, 753-8.	1.2	8

SOTARO SADAHIRO

#	Article	IF	CITATIONS
55	Prevention of Hepatic Artery Occlusion During Continuous Infusion of Fluorouracil Using Liposteroid. American Journal of Roentgenology, 2000, 175, 1641-1642.	1.0	7
56	Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer. International Journal of Clinical Oncology, 2017, 22, 494-504.	1.0	7
57	A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer. Oncology, 2015, 88, 353-359.	0.9	6
58	Gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for the proper use of S-1 and tegafur-uracil/leucovorin in preoperative chemoradiotherapy for patients with rectal cancer. Cancer Chemotherapy and Pharmacology, 2017, 79, 1077-1085.	1.1	6
59	Predictors of tumor downsizing and regression with preoperative radiotherapy alone and with concomitant tegafur/uracil (UFT) for resectable advanced rectal adenocarcinoma. Hepato-Gastroenterology, 2007, 54, 1107-12.	0.5	6
60	Optimal suture materials for contaminated gastrointestinal surgery: does infection influence the decrease of the tensile strength of sutures?. Surgery Today, 2012, 42, 1170-1175.	0.7	5
61	A Modified Classification of Prognostic Factors Based on Pathological Stage and Tumor Regression Grade in Patients with Rectal Cancer Who Receive Preoperative Chemoradiotherapy. Oncology, 2017, 93, 287-294.	0.9	5
62	Development and validation of a prognostic nomogram for colorectal cancer after radical resection based on individual patient data from three large-scale phase III trials. Oncotarget, 2017, 8, 99150-99160.	0.8	5
63	Preliminary study of the optimal dosing schedule for oral UFT/leucovorin chemotherapy. Anticancer Research, 2004, 24, 625-30.	0.5	5
64	Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201). BMC Cancer, 2022, 22, 170.	1.1	5
65	Predictive markers of chemoradiotherapy for rectal cancer: comparison of biopsy specimens taken before and about 1Âweek after the start of chemoradiotherapy. International Journal of Clinical Oncology, 2015, 20, 1130-1139.	1.0	4
66	Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial. Oncology, 2020, 98, 637-642.	0.9	4
67	Tissue-Infiltrating Lymphocytes as a Predictive Factor for Recurrence in Patients with Curatively Resected Colon Cancer: A Propensity Score Matching Analysis. Oncology, 2020, 98, 680-688.	0.9	4
68	A prospective clinical study assessing the presence of exfoliated cancer cells and rectal washout including tumors in patients who receive neoadjuvant chemoradiotherapy for rectal cancer. Surgery Today, 2020, 50, 352-359.	0.7	3
69	The stability of dihydropyrimidine dehydrogenase activity in colorectal cancer tissue after resection. Oncology Reports, 2003, 10, 867-9.	1.2	3
70	Dihydropyrimidine Dehydrogenase Activity during Long-Term Adjuvant Treatment with Oral Uracil and Tegafur for Colorectal Cancer. Chemotherapy, 2007, 53, 442-445.	0.8	2
71	Risk factors associated with recurrence by peritoneal dissemination or paraaortic lymph node metastasis after curative surgery in patients with colorectal cancer. Annals of Cancer Research and Therapy, 2016, 24, 58-59.	0.1	2
72	Chemoradiotherapy-induced Changes in Mucinous Components in Rectal Cancer Tissue: Evaluation on High Iron Diamine-alcian Blue and Mucin 1 Staining. Anticancer Research, 2018, 38, 4783-4787.	0.5	2

SOTARO SADAHIRO

#	Article	IF	CITATIONS
73	Induction of CD3+ and FoxP3+ T Cells in Left-sided Colorectal Tumors After UFT/LV Chemotherapy. Anticancer Research, 2019, 39, 1997-2005.	0.5	2
74	Discovery of Inhibitors of Membrane Traffic from a Panel of Clinically Effective Anticancer Drugs. Biological and Pharmaceutical Bulletin, 2019, 42, 814-818.	0.6	2
75	Comparison of clinic pathological characters and survival between right- and left-side colon cancer. Annals of Cancer Research and Therapy, 2016, 24, 62-63.	0.1	2
76	Reduction in Î ³ -glutamyl hydrolase expression is associated with response to uracil and tegafur/leucovorin chemotherapy in patients with colorectal cancer. Anticancer Research, 2013, 33, 3431-8.	0.5	2
77	Increase in Gene Expression of TYMP, DPYD and HIF1A Are Associated with Response to Preoperative Chemoradiotherapy Including S-1 or UFT for Rectal Cancer. Anticancer Research, 2016, 36, 2433-40.	0.5	2
78	Prediction of Recurrence in Patients with Stage III Colon Cancer Using Conventional Clinicopathological Factors and Peripheral Blood Test Data: A New Analysis with Artificial Intelligence. Oncology, 2021, 99, 318-326.	0.9	1
79	Clinical features of colorectal mucinous and poorly differentiated adenocarcinomas; study concept of a propensity score analysis in a pooled data of 5530 patients. Annals of Cancer Research and Therapy, 2016, 24, 52-53.	0.1	1
80	The relation between postoperative surgical complications and colorectal cancer survival. Annals of Cancer Research and Therapy, 2016, 24, 54-55.	0.1	1
81	A Case of Panperitonitis Caused by Rupture of the Urinary Bladder due to Gangrenous Cystitis. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2014, 75, 2883-2887.	0.0	1
82	Two Patients with Aggressive Angiomyxoma of the Pelvis who Received Neoadjuvant Hormone Therapy. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2016, 77, 1818-1826.	0.0	1
83	The Optimum Duration of Perioperative Prophylactic Antibiotic Adminidtration in Patients with Rectal Cancer—A Randomized Clinical Trial—. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan) Tj ETQq1	100078432	l ⊕ rgBT /Ove
84	Hazard rate of tumor recurrence over time: a pooled-analysis of three clinical trials with fluoropyrimidine-based adjuvant chemotherapy for colorectal cancer achieved by the Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC). Annals of Cancer Research and Therapy, 2016, 24, 60-61.	0.1	0
85	Prognostic Nomogram for Colorectal Cancer after Radical Resection in Japanese population. Annals of Cancer Research and Therapy, 2016, 24, 56-57.	0.1	0
86	Risk factors for paraaortic lymph-node recurrence in colorectal cancer. Annals of Cancer Research and Therapy, 2019, 27, 52-56.	0.1	0
87	Long-term postoperative adjuvant chemotherapy of UFT/LV improves survival in a primary tumor resection-pulmonary metastasis model. Anticancer Research, 2008, 28, 2045-8.	0.5	0
88	Predictors and histological effects of preoperative chemoradiotherapy for rectal cancer and control of lateral lymph node metastasis. BMC Gastroenterology, 2022, 22, .	0.8	0